Before the opening bell, the Oakland, CA-based maker of consumer products posted earnings of $1.36 per diluted share, below analysts' forecasts of $1.42 per share.
Revenue for the period was $1.44 billion, while analysts had projected $1.43 billion.
"As we look to the remainder of the fiscal year, I feel good about the health of our core business and am confident in the strategic plans we have in place in the face of a challenging macro-economic environment," CEO Benno Dorer said in a statement.
Clorox continues to see full-year earnings per diluted share between $5.13 and $5.28. Analysts surveyed by FactSet are projecting earnings of $5.48 per share for fiscal 2017.
Separately, TheStreet Ratings Team has a "Buy" rating with a score of B on the stock.
The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and notable return on equity. The team believes its strengths outweigh the fact that the company has had sub par growth in net income.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: CLX